The Billion-Dollar Problem Keeping Ozempic, Wegovy, and Zepbound From Patients
Researchers say many plans still restrict GLP-1 drugs even as a recent analysis found the medications deliver strong value, with obesity affecting about 40% of Americans.
3 Articles
3 Articles
The billion-dollar problem keeping Ozempic, Wegovy, and Zepbound from patients
Ozempic, Wegovy, and similar drugs may deliver excellent health value, but covering them for millions of eligible patients could overwhelm insurance budgets. Researchers say better long-term support is needed and warn that low-cost compounded versions may carry serious safety risks.
What Would You Do to Protect $50 Billion a Year?
By Amanda Frost, PhD Vice President, Research, PCMA Did you know: the original patent for semaglutide – better known as Ozempic – should have expired this year. Today, incredible hope for human health rests in drugs like semaglutide. But they highlight the tension between breakthroughs in medicine and access to these promising therapies. They also reveal the lengths drugmakers will go to block competition and keep prices high. Let’s dive into th…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
